Differential cardiac impacts of hematological malignancies and solid tumors: a histopathological and biomarker study

被引:1
|
作者
Udin, Michael H. [1 ,4 ,5 ,7 ]
Sunder, Sunitha Shyam [1 ]
Nepali, Sarmila [1 ]
Kattel, Sharma [2 ]
Abdelradi, Amr [3 ]
Doyle, Scott T. [4 ]
Ionita, Ciprian N. [4 ,5 ]
Liu, Qian [6 ]
Sharma, Umesh C. [7 ]
Pokharel, Saraswati [1 ]
机构
[1] Roswell Park Comprehens Canc Ctr, Dept Pathol & Lab Med, Buffalo, NY 14203 USA
[2] Univ Minnesota, Dept Med, Div Cardiovasc Med, Minneapolis, MN USA
[3] Univ Buffalo, Sch Med & Biomed Sci, Dept Med, Div Cardiol, Buffalo, NY USA
[4] Univ Buffalo, Dept Biomed Engn, Buffalo, NY USA
[5] Canon Stroke & Vasc Res Ctr, Buffalo, NY USA
[6] Roswell Park Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA
[7] Univ Buffalo, Sch Med & Biomed Sci, Dept Med, Buffalo, NY USA
关键词
Cardiotoxicity; Cancer; Cancer therapy; Hematological malignancy; Solid tumor; Heart failure; Fibrosis; Collagen; Second harmonic generation; Acute myeloid leukemia; CARDIOVASCULAR-DISEASE; CANCER; LEUKEMIA; RISK; PREVALENCE; DIAGNOSIS; SURVIVORS;
D O I
10.1186/s40959-024-00285-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Cancer patients are known to be associated with increased risk of cardiovascular disease. However, no studies have examined the differential impact of hematologic malignancies (HMs) and solid tumors (STs) on cardiac morphology at the tissue level. Objective We aimed to examine histopathological features alongside cardiovascular biomarkers in patients with HMs and STs who underwent post-mortem evaluation. Methods We analyzed cardiac changes in 198 patients with HMs and 164 patients with solid tumors STs. We compared demographics, echocardiogram data, exposure to various antineoplastic agents, and post-mortem findings. Additionally, cardiac histological validation was conducted on post-mortem cardiac specimens to examine cardiac tissue morphology, focusing on cardiomyocyte nuclear density, collagen content, and collagen fiber orientation. Results HM patients displayed significantly disordered collagen fiber alignment (0.71 vs 0.83, P = 0.027), and reduced cardiomyocyte nuclear density (56 vs 72, P = 0.002) compared to ST patients. Similarly, hemoglobin level was decreased (6.71 vs 8.06, P < 0.001) in HM patients compared to ST patients. HM patients also showed elevated B-type natriuretic peptide levels (2,275 vs 867, P < 0.001), without significant differences in creatine-kinase MB and cardiac troponin levels. Multivariate analysis identified increased right ventricular thickness, low diastolic blood pressure, and high cardiac troponin levels as risk factors for cardiac death in HM patients. Conclusions This study demonstrates that HM patients have fewer cardiomyocyte nuclei and poorly aligned collagen, with serum biomarker evidence of increased cardiac dysfunction. This supports the necessity for specialized cardiac care for these patients.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Long-term outcomes and quality of life in critically ill patients with hematological or solid malignancies: a single center study
    Oeyen, S. G.
    Benoit, D. D.
    Annemans, L.
    Depuydt, P. O.
    Van Belle, S. J.
    Troisi, R. I.
    Noens, L. A.
    Pattyn, P.
    Decruyenaere, J. M.
    INTENSIVE CARE MEDICINE, 2013, 39 (05) : 889 - 898
  • [32] Long-term outcomes and quality of life in critically ill patients with hematological or solid malignancies: a single center study
    S. G. Oeyen
    D. D. Benoit
    L. Annemans
    P. O. Depuydt
    S. J. Van Belle
    R. I. Troisi
    L. A. Noens
    P. Pattyn
    J. M. Decruyenaere
    Intensive Care Medicine, 2013, 39 : 889 - 898
  • [33] Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors
    Staib, P
    Hoffmann, M
    Schinköthe, T
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2006, 44 (01) : 28 - 31
  • [34] Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies
    Puxeddu, Michela
    Shen, Hongliang
    Bai, Ruoli
    Coluccia, Antonio
    Nalli, Marianna
    Mazzoccoli, Carmela
    Da Pozzo, Eleonora
    Cavallini, Chiara
    Martini, Claudia
    Orlando, Viviana
    Biagioni, Stefano
    Mazzoni, Cristina
    Coluccia, Addolorata Maria Luce
    Hamel, Ernest
    Liu, Te
    Silvestri, Romano
    La Regina, Giuseppe
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 185
  • [35] Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies
    Wong, Chiung-Ing
    Koh, Tong-San
    Soo, Ross
    Hartono, Septian
    Thng, Choon-Hua
    McKeegan, Evelyn
    Yong, Wei-Peng
    Chen, Chien-Shing
    Lee, Soo-Chin
    Wong, John
    Lim, Robert
    Sukri, Norita
    Lim, Siew-Eng
    Ong, Ai-Bee
    Steinberg, Joyce
    Gupta, Neeraj
    Pradhan, Rajendra
    Humerickhouse, Rod
    Goh, Boon-Cher
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4718 - 4726
  • [36] Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: A national cohort study
    Ji, Jianguang
    Zoller, Bengt
    Sundquist, Jan
    Sundquist, Kristina
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (04) : 754 - 758
  • [37] Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological malignancies and solid tumors
    Takeshita, Kenichi
    Ishiwada, Naruhiko
    Takeuchi, Noriko
    Ohkusu, Misako
    Ohata, Mihoko
    Hino, Moeko
    Hishiki, Haruka
    Takeda, Yusuke
    Sakaida, Emiko
    Takahashi, Yoshiko
    Shimojo, Naoki
    Hamada, Hiromichi
    VACCINE, 2022, 40 (09) : 1238 - 1245
  • [38] Incidence patterns of childhood non-Wilms renal tumors: Comparing data of the Nationwide Registry of Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST), Greece, and the Surveillance, Epidemiology, and End Results Program (SEER), USA
    Doganis, Dimitrios
    Karalexi, Maria A.
    Panagopoulou, Paraskevi
    Bouka, Panagiota
    Bouka, Evdoxia
    Markozannes, Georgios
    Ntzani, Evangelia E.
    Steliarova-Foucher, Eva
    Petridou, Eleni Th
    CANCER EPIDEMIOLOGY, 2022, 78
  • [39] Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
    Wong, A. L.
    Soo, R. A.
    Tan, D. S.
    Lee, S. C.
    Lim, J. S.
    Marban, P. C.
    Kong, L. R.
    Lee, Y. J.
    Wang, L. Z.
    Thuya, W. L.
    Soong, R.
    Yee, M. Q.
    Chin, T. M.
    Cordero, M. T.
    Asuncion, B. R.
    Pang, B.
    Pervaiz, S.
    Hirpara, J. L.
    Sinha, A.
    Xu, W. W.
    Yuasa, M.
    Tsunoda, T.
    Motoyama, M.
    Yamauchi, T.
    Goh, B. C.
    ANNALS OF ONCOLOGY, 2015, 26 (05) : 998 - 1005
  • [40] The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors
    Coker, Shodeinde A.
    Hurwitz, Herbert I.
    Sharma, Sunil
    Wang, Ding
    Jordaan, Pierre
    Zarate, Juan Pablo
    Lewis, Lionel D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 383 - 392